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ABSTRACT
The Apoptotic and Inhibitory Effects of Phylloquinone in the U937 Cell Line
by
Tesha Blair
Phylloquinone is a natural analog of vitamin K that has been shown to both inhibit
cancer cell growth and induce apoptosis in several cancer cell lines. This study
examined these effects in a non-Hodgkin lymphoma cell line, known as U937. Cell
growth inhibition and apoptosis were assessed through the quantification of cell
density and area, following treatment with several concentrations of phylloquinone.
In addition, apoptosis was detected and quantified using immunofluorescent
markers of apoptosis (i.e. annexin V, APO-BrdU). Treatment with phylloquinone
resulted in reduced overall cell density, increased overall cell area, and an increased
frequency of apoptosis in U937 cells. Increasing both phylloquinone concentration
and treatment time enhanced these effects. These results are significant because
they document the anti-cancer effects of this analog of vitamin K, as well as provide
insight into the morphological changes that occur during apoptosis in U937 cells.
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CHAPTER 1
INTRODUCTION

The National Institute of Health estimates the allocation of $9.3 billion
dollars to fund cancer-related research for the year of 2017 (National Institute of
Health 2016). This comes as no surprise, considering the millions of cancer fatalities
worldwide every year. Risk factors like nutritional deficiencies, environmental
toxins, transmission of disease, and an ever-growing and aging population directly
contribute to the rising number of new cancer cases (Peterson et al. 2012; Howell et
al. 2014; American Cancer Society 2015). The World Health Organization predicts
that by 2035, the worldwide rates of cancer morbidity and mortality will reach 24
million and 14.6 million, respectively (National Cancer Institute 2015). In order to
combat this epidemic, more effective and accessible treatments need to be
developed. Many researchers are currently interested in the relationship between
cell proliferation and cell death – specifically, the dysregulation of genetically
directed cell death pathways, like apoptosis, in the proliferation of aberrant cells,
and how this relationship can be used to design more promising cancer treatment
therapies (Lowe and Lin 2000).

Apoptosis
The earliest documentation of cell death dates back to 1842, when a German
scientist named Carl Vogt published a study on the degeneration of cells during
metamorphosis of the common midwife toad (Alytes obstetricans) (Clarke and
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Clarke 2012). A little over forty years later, another German scientist named Walter
Flemming characterized the morphological changes of non-necrotic cell death in his
publication on ovarian follicular cell atresia, which is a normal process of
menstruation (Lockshin and Zakeri 2001). It was not until 1972 that the term
“apoptosis” was first proposed by pathologists John Foxton Ross Kerr, Andrew H.
Wyllie, and Alastair Robert Currie, to describe a type of cell death morphologically
separate from necrosis, as well as one that is fundamental to the homeostatic
balance between cell division and cell death in normal animal cell populations (Kerr
et al. 1972; Bold et al. 1997; Jiang 2011). Since the recognition that apoptosis is a
genetically regulated event that occurs both during normal development and aging,
and in response to various internal and external stimuli, many scientists have been
interested in the factors affecting this type of cell death, as well as the biochemical
and molecular pathways coordinating their effect (Williams and Smith 1993; Elmore
2007).
Kerr, Wyllie, and Currie derived the term “apoptosis” from the Greek word
“αποπτωσισ”, which translates to the “dropping off” or “falling off” of flower petals
or tree leaves, to describe the structural changes they observed in a variety of
tissues with electron microscopy, including neonatal rat adrenal cortexes and
human neoplasms (Kerr et al. 1972). This derivation was likely selected because it
implies that the death or loss of a specific part of an organism is fundamental to the
continuation of its life cycle. Prior to this time, the morphology of cell death
described in most scientific texts was characteristic of coagulative or classical
necrosis, and therefore apoptosis was seen as a distinct subtype of necrosis, known
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as “shrinkage necrosis”, with markedly different morphological changes (Kerr 1971;
Kerr 2002). The process of apoptosis, as first described by Kerr, Wyllie, and Currie
in 1972, generally affects individual cells scattered throughout cell populations, and
occurs in two discrete stages. The first stage consists of the formation of apoptotic
bodies, which are preserved cellular fragments containing organelles, condensed
cytoplasm, and/or condensed nuclear chromatin, which are chemically and
structurally intact. The second stage of apoptosis consists of the phagocytosis and
subsequent degradation of apoptotic bodies by nearby cells (Kerr et al. 1972; Kerr
et al. 1994).

Morphology
The formation of apoptotic bodies occurs through a series of coordinated
events. The apoptotic cell undergoes simultaneous nuclear shrinkage or pyknosis,
membrane blebbing or the appearance of protrusions along the cell’s surface, and
cytoplasmic condensation (Kerr et al. 1972). This is followed by nuclear
fragmentation or karyorrhexis, and finally, the separation of protuberances along
the cell’s surface to form membrane-bound apoptotic bodies (Kerr et al. 1972;
Majno and Joris 1995). The term “budding” has also been used to refer to the
formation of apoptotic cell bodies (Kerr et al. 1994; Majno and Joris 1995).
Apoptotic bodies can contain any cellular components that were near or in the
cytoplasmic protrusion before budding occurred, including cytoplasmic elements,
condensed organelles, and condensed nuclear chromatin. Although size and
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composition is highly variable between bodies, the structural and chemical integrity
of their contents is preserved (Kerr et al. 1972; Kerr et al. 1994).
Following the release of chemoattractants and surface signals, apoptotic
bodies are rapidly phagocytized by a variety of adjacent cell types, including
macrophages, neoplastic cells, epithelial cells, or fibroblasts, and undergo lysosomal
degradation (Kerr et al. 1972; Majno and Joris 1995; Elmore 2007; Elliot and
Ravichandran 2010). A renowned feature of apoptosis is that, unlike necrosis, no
inflammation results from the displacement of cellular bodies (Kerr et al. 1994;
Majno and Joris 1995). There are several reasons why apoptosis does not provoke
an inflammatory response: (1) apoptotic bodies are membrane-bound, so cellular
contents are not spilled into interstitial tissues surrounding the cell, (2) bodies are
quickly engulfed by nearby cells, inhibiting secondary necrosis, and (3) antiinflammatory cytokines are not produced by phagocytic cells (Martin and Green
1995; Elmore 2007; Silva 2010). Due to this lack of inflammation, apoptosis
represents a promising way to ensure specific cell death without damage to
surrounding healthy tissues.

Programmed Cell Death and Cell Suicide – Incidence of Apoptosis
Programmed cell death (PCD) and cell suicide are both terms used to
describe apoptosis, although they have alternate connotations. PCD denotes cell
death that is genetically predetermined, while cell suicide implies an inducible or
spontaneous form of cell death. The pervasiveness of these expressions has led to
some ambiguity in regards to the circumstances surrounding apoptosis (Majno and
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Joris 1995). In truth, apoptosis can be predetermined or inducible depending on the
life stage of the organism and its environment. This type of cell death has two major
roles – one is to ensure the existence of healthy cells, the other is to diminish the
existence of unhealthy ones (Kerr et al. 1994). In this way, PCD can generally be
applied to the role of apoptosis in healthy cell populations, while cell suicide can be
used to depict the role of apoptosis in unhealthy ones.
Apoptosis ensures the proliferation of healthy cells through the regulated
deletion of cells that are overabundant, or cells that have lost their function or
become superfluous over time (Kerr et al. 1972; Martin and Green 1995). During
ontogenesis, and particularly throughout embryogenesis, the controlled deletion of
overabundant cells is necessary for shaping an organism’s developing tissues and
organs (Martin and Green 1995; Abud 2004). A renowned example of apoptosis
during embryogenesis occurs in primates, where one of its many responsibilities is
the elimination of the interdigital webbing of the hand or foot to form fingers and
toes (Dorn 2013). Apoptosis is also critical to the excision of cells that are no longer
needed or have lost their function during events like metamorphosis and aging
(Martin and Green 1995). During amphibian metamorphosis, for example, this type
of cell death is responsible for the removal of the tadpole’s tail as it matures into an
adult frog (Kerr et al. 1974). These events provide examples of apoptosis that are
genetically programmed or predetermined, and are essential to the growth or
maintenance of healthy cell populations.
Apoptosis diminishes the existence of unhealthy or abnormal cells in
response to a number of factors, including mutation and disease (Martin and Green
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1995; Elmore 2007). It goes without saying that the accumulation of aberrant cells
compromises the body’s ability to defend itself. Therefore, in individuals with
normal physiology, the induction of apoptosis is one of first lines of defense in or
against cells that are structurally and functionally damaged (Kerr et al. 1994).
Without this inducible form of cell death, cell populations would accumulate more
mutations and be more susceptible to a variety of diseases. For instance, there is a
strong correlation between modified apoptotic pathways resulting in less cell death
and an increased incidence of cancer (Kerr et al. 1994; Bold et al. 1997). Other
examples of the relationship between reduced apoptosis and enhanced morbidity
include increased susceptibility to viral infection, like Epstein-Barr and adenovirus,
as well as to autoimmune disease, like lupus and rheumatoid arthritis (Solary et al.
1996). Typically, the ability to engage in cell suicide is beneficial to the specific cell
population, and therefore, many pathologic states arise from an inability to engage
in this form of cell death. There are instances, however, when modifications causing
the upregulation of this cell death pathway can accelerate the progression of a
disorder or disease (Elmore 2007). This is exemplified by viruses that can induce
apoptosis to aid in their own propagation, by either causing an infected cell to die
and release its viral constituents (e.g. Avian Reovirus) or causing the death of an
immune cell, so that it is unable to phagocytize the virus (e.g. HIV and influenza A
and B viruses) (Hinshaw et al. 1994; Elmore 2007; Rodríguez-Grille et al. 2014).
These examples provide evidence of the role of this inducible form of cell death in
diminishing the existence of unhealthy cells, as well as the some of the
consequences of modulations to these pathways.
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Biochemical Mechanisms
The mechanisms of apoptosis can be divided into two major pathways: the
extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway
(Elmore 2007). Both pathways are mediated by caspases, a group of cysteine
proteases, which remain in their zymogenic form until they receive an apoptotic
stimulus (Johnstone et al. 2002). Once active, caspases engage in a caspase cascade
where upstream or initiator caspases (e.g. caspases 2, 8, 9, 10) cleave downstream
or effector caspases (e.g. caspases 3, 6, 7), which, in turn, cleave various cellular
proteins that regulate apoptotic cell death (Chang and Yang 2000; Turk and Stoka
2007). The extrinsic pathway of apoptosis is initiated when an extrinsic ligand binds
to a membrane-bound member of the tumor necrosis factor (TNF) receptor
superfamily (e.g. TRAIL receptor 1, Fas receptor), which is commonly referred to as
a “death receptor” (Johnstone et al. 2002; Wang and El-Deiry 2003). Binding of these
receptors results in the activation of initiator caspases 8 and 10, which activate
effector caspases 3 and 7 (Johnstone et al. 2002). These caspases then activate a
network of proteins and orchestrate numerous processes that lead to apoptotic cell
death (Chang and Yang 2000; Elmore 2007).
The intrinsic pathway of apoptosis is initiated when the cell is exposed to
DNA damage, free radicals, radiation, viral infections, and other types of cell stress
(Wang and El-Deiry 2003). These stimuli activate pro-apoptotic members of the Bcl2 superfamily (e.g. PUMA, Bax, Bak), which modify the integrity of the inner
mitochondrial membrane and result in the release of several pro-apoptotic proteins
(e.g. cytochrome c, Smac, Omi) into the cytosol (Johnstone et al. 2002; Turk and
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Stoka 2007). Cytochrome c activates apaf1, which is needed for the formation of an
apoptosome, a quaternary protein structure containing cytochrome c and apaf1, and
the activation of initiator caspase 9 (Johnstone et al. 2002; Turk and Stoka 2007).
The activation of caspase 9 triggers a caspase cascade and activates effector
caspases 3, 6, and 7, whilst Smac and Omi bind to and antagonize several antiapoptotic proteins (Johnstone et al. 2002). Again, this cascade ultimately leads to
activation and induction of a variety of proteins and processes that lead to apoptotic
cell death (Chang and Yang 2000; Elmore 2007). There is evidence of crosstalk
between the pathways: caspase 8 can activate another Bcl-2 family member, Bid,
which can induce the release of cytochrome c in the mitochondria through
interaction with Bax and Bak (Johnstone et al. 2002; Wang and El-Deiry 2003).
A third apoptotic pathway does exist, but it is limited to natural killer cells
and cytotoxic T cells. These cells secrete a serine protease called granzyme B, which
is similar to caspases because they both cleave other proteins directly following an
aspartic acid residue (Turk and Stoka 2007). When natural killer cells or cytotoxic T
cells encounter a target cell, they can secrete granzyme B, along with perforin, and
engage in the extrinsic pathway through cleavage of caspase 3 or in the intrinsic
pathway through cleavage of Bid (Turk and Stoka 2007). Another serine protease,
granzyme A, is secreted by cytotoxic T cells and can induce apoptosis through a
caspase independent pathway involving tumor suppressor gene, NM23-H1 (Elmore
2007). Granzyme A cleaves NM23-H1 antagonist SET, which activates NM23-H1 and
results in apoptotic DNA degradation (Elmore 2007).
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Apoptosis and Cancer
Apoptosis is fundamental to the homeostasis of healthy cell populations –
that is, the balance between cell growth and division, as well as cell death. Any
disruption to this balance will therefore result in numerous pathologic states,
including cancer (Kerr et al. 1972; Alberts et al. 2002). Cancer is the result of defects
or modifications to genes controlling cell proliferation and differentiation, as well as
those controlling cell death (Martin and Green 1995). With regards to cell death,
specifically apoptosis, there are two major categories of genes: repressors or antiapoptotic genes and inducers or pro-apoptotic genes. As their names suggest,
repressors inhibit or postpone apoptosis, while inducers provoke it or increase the
likelihood that it will occur (Martin and Green 1995). Mutations or modifications to
the expression levels of repressors and/or inducers in both apoptotic pathways, as
well as their upstream and downstream components, are common to many cancer
and tumor types, although these changes more often occur in members of the
intrinsic or mitochondrial pathway (Martin and Green 1995; Johnstone et al. 2002).
The p53 tumor suppressor gene is a checkpoint protein that is essential to
the regulation of both the cell cycle and cell death (Kerr et al. 1994; Bold et al. 1997;
Lowe and Lin 2000). p53 allows cells to respond to DNA damage by arresting the
cell cycle and attempting DNA repair, when its levels are low or moderate, and
inducing apoptosis when its levels are high (Bold et al. 1997). The wild-type p53
allele is an intrinsic inducer of apoptosis and is responsible for the transcriptional
activation of Bcl-2 family inducers (e.g. Bax, Bak, PUMA) and repression of Bcl-2
family suppressors (e.g. Bcl-2, Bcl-X) (Johnstone et al. 2002). The loss of function
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that occurs in mutant p53 alleles has been found to both inactivate apoptosis and
accelerate tumor formation, and has been observed in the vast majority of human
cancer types, including lung, colon, breast, prostate, and pancreas, (Bold et al. 1997;
Lowe and Lin 2000; Johnstone et al. 2002). For this reason, functional mutations of
p53 are associated with advanced stage cancer and high mortality (Lowe and Lin
2000). In addition to changes in p53 itself, mutations or modified expression of its
upstream regulators (e.g. ATM, Mdm 2) or downstream effectors (e.g. Bax, Bak,
Apaf1) have been found in many tumor types including leukemia and melanoma, as
well as colon, gastric, and breast cancers (Lowe and Lin 2000; Johnstone et al.
2002).
Functional mutations or altered expression of Bcl-2 family members are also
associated with cancer cell proliferation through a failure to induce apoptosis (Lowe
and Lin 2000; Johnstone et al. 2002). In mammalian cells, fifteen Bcl-2 family
members have been identified and consist of both repressors and inducers of
apoptotic cell death (Lowe and Lin 2000). Bcl-2, itself, was originally characterized
as a proto-oncogene because of its location on a breakpoint in human B-cell
lymphomas, following chromosomal translocation (Kerr et al. 1994; Lowe and Lin
2000). Bcl-2 was later determined to inhibit apoptosis, rather than promote
proliferation, in interleukin-3-depedent myeloid and lymphoid cell lines, following
interleukin-3 deprivation (Ascaso et al. 1994; Kerr et al. 1994; Lowe and Lin 2000).
Bcl-2 is an intrinsic repressor of apoptosis, and its overexpression has been
significantly associated with both cancer development and metastasis, and has been
estimated to occur in approximately half of all cancers (Bold et al. 1997; Johnstone
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et al. 2002; Yip and Reed 2008). The inactivation or reduced expression of Bcl-2
family inducers of apoptosis, like Bax and Bak, result in an inability to suppress
tumor growth by the induction of apoptosis, and have been identified in different
tumor types, including colon, stomach, breast, gastric and hematopoietic cancers
(Ouyang et al. 1998; Lowe and Lin 2000; Johnstone et al. 2002; Yip and Reed 2008;
Kholoussi et al. 2014). Like p53, changes to the expression or function of Bcl-2
upstream components are associated with the dysregulation of apoptosis and result
in tumorigenesis (Johnstone et al. 2002).
Disturbances to members of the extrinsic or death receptor apoptotic
pathway are less common, although they have been found in tumor cells and result
in an inability to undergo apoptosis following the binding of death receptors
(Johnstone et al. 2002). Members of this pathway that commonly experience
disruption include Fas receptor and TRAIL receptors 1 and 2 (Johnstone et al. 2002;
Johnstone et al. 2008). Fas receptor, also known as Apo-1 or C95, is normally an
extrinsic inducer of apoptosis and is responsible for the recruitment of the adaptor
protein FADD and activation of membrane-proximal initiator caspases 8 and 10
(Lowe and Lin 2000; Johnstone et al. 2002; Johnstone et al. 2008). Since the
proteolytic cleavage of caspase 8 results in the activation of its downstream
components (e.g. caspases 3 and 7) in the extrinsic pathway or the activation of
intrinsic pathway member Bid, functional mutations of this death receptor increases
a tumor cell’s resistance to apoptosis in either pathway (Johnstone et al. 2002).
Autoimmune lymphoproliferative syndrome (ALPS) is a disorder marked by an
inability to regulate the body’s lymphocyte population due to a Fas receptor defect.
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In this disorder, aberrant T-lymphocytes are able to evade apoptosis, and therefore,
the frequency of lymphoma cancers in patients with ALPS is significantly increased
(Johnstone et al. 2002). TRAIL receptor 1, otherwise known as Apo-2, and TRAIL
receptor 2, are, like other members of the TNF receptor superfamily, responsible for
the induction of apoptosis following the binding of extracellular ligands (e.g. TRAIL).
Mutations in TRAIL receptors 1 and 2 and their downstream effectors (e.g. caspases
8 and 10) have been detected in a number of cancer types, including hematopoietic
and breast cancers (Johnstone et al. 2008). In addition to encouraging tumorigenesis
through the inhibition of apoptosis, alterations in extrinsic pathway death receptors
appear to alter immune system surveillance, thereby promoting metastasis (Bold et
al. 1997; Johnstone et al. 2002; Johnstone et al. 2008).

Apoptosis and Cancer Therapy
Traditional cancer therapy consists of a combination of surgery and cytotoxic
agents, like chemotherapy and radiation. Surgery was first used to eliminate whole
tumors, as well as lymph nodes, following the advent of anesthesia in the midnineteenth century (Sudhakar 2009). Medical imaging, like ultrasound and MRI,
were developed in the 1970s, and improved the efficacy of tumor excision by
reducing exploratory surgery (Sudhakar 2009). The use of cytotoxic agents, in
combination with surgery, also greatly improved the effectiveness of cancer
treatment (Sudhakar 2009). Chemotherapy, itself, was first used in the 1940s when
researchers studied mustard gas and compounds related to it in order to develop
better chemical warfare, as well as to develop better treatments against it (Sak
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2012; American Cancer Society 2014). During this time, American pharmacologists,
Louis Goodman and Alfred Gilman, reviewed the medical records of soldiers
exposed to mustard gas in WWI and found that many of them suffered immune cell
reduction (Sak 2012; Hazell 2014). In 1942, Goodman and Gilman administered
mustard gas to a patient with lymphoma, after hypothesizing that if it has the
capability to reduce normal immune cells, it should also be able to reduce cancerous
ones. The administration of the mustard gas was found to alleviate some of the
patient’s discomfort (Hazell 2014). In 1948, Scottish chemist Alexander Haddow
studied the component of mustard gas responsible for cytotoxicity and found that
this component, called nitrogen mustard, induced cellular suicide with higher
specificity than mustard gas (Hazell 2014). The use of radiation to treat cancer was
discovered even earlier than chemotherapy, in 1896, when American scientist Emil
Grubbe used radiation to treat a woman with breast cancer, and found that it briefly
improved her condition (Markel 2015).
By the end of the 20th century, with more advanced surgical techniques, a
larger variety of chemotherapeutic agents, and more precise delivery of
chemotherapy and radiation (chemoradiation), cancer therapy had greatly
improved (Sudhakar 2009). Traditional cancer therapies were further enhanced
with increased understanding and evidence of the mechanisms responsible for cell
death, as well as how these mechanisms were modified in different cancer types.
Modern chemotherapy, therefore, came to be known as targeted cancer therapy.
Targeted cancer therapy differs from traditional chemotherapy in that drugs, which
can be cytostatic or cytotoxic, are designed or selected to act on specific molecular
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targets, whereas traditional chemotherapy destroyed all cells to which it was
administered (i.e. both healthy and cancerous cells) (National Cancer Institute
2014). Gene therapy is also often employed, alongside targeted cancer therapy, to
increase the effectiveness of chemotherapeutic agents or to reestablish tumor
sensitization to them.
Much of the current research on the relationship between apoptosis and
cancer is concerned with the modifications in the pathways controlling apoptosis
(e.g. p53) and how these can be utilized to improve targeted cancer and gene
therapies (Lowe and Lin 2000). For example: Due to its involvement of p53 in
apoptosis, many cancer treatments are concerned with targeting it with
chemoradiation or restoring its function with gene therapy (Wang and Sun 2010).
Traditional cancer therapies, like chemotherapy and radiation, are able to
upregulate p53 by damaging cellular DNA and, therefore, increase apoptosis (Wang
and Sun 2010). Since many cancer types are associated with mutations in p53,
chemoradiation is often inappropriate and associated with drug resistance (Bold et
al. 1997; Lowe and Lin 2000; Johnstone et al. 2002). Gene therapy allows the
restoration of p53, and apoptosis, through viruses that reintroduce the wild-type
allele or small molecules that bind to p53 and block the binding of its competitive
inhibitors (Issaeva et al. 2004; Wang and Sun 2010). For instance, replicationdeficient adenovirus (Ad-p53) was successfully used to reintroduce wild-type p53
to human lung cancer cells, and is now marketed under the brand name of
Gendicine/Advexin for treatment of head, neck, and lung cancers (Wang and Sun
2010). ONYX-015 is an E1B-deleted adenovirus, currently in clinical trials, that

24

selectively replicates in and lyses cancer cells that do not express functional p53
(Wang and Sun 2010). RITA is the name of a small molecule that has been used to
reactivate p53 by preventing the binding of Mdm2, an inhibitor of p53, as well as
other repressors of apoptosis, including Mcl-1 and Bcl-2 (Issaeva et al. 2004; Wang
and Sun 2010).

Vitamins and Cancer Therapy
The use of cancer therapies to upregulate p53 or modify its functionality, in
order to induce apoptosis, provide evidence of the myriad possibilities that exist
with both traditional and modern cancer treatments, as well as the challenges in
integrating these approaches. Another emerging area of cancer research and
integration is the use of vitamins and dietary metabolites, like vitamins C, D, E, and
K, as primary or supplementary means of inducing apoptosis (Mathiasen et al. 1999;
Sakagami et al. 2000; Sylvester 2007; Karasawa et al. 2013). Various types of
vitamin K, for instance, have been shown to induce apoptosis and inhibit cell growth
in a number of cancer types, including leukemia, lung, myeloma, and lymphoma,
through the modification of members of both apoptotic pathways (Yaguchi et al.
1997; Yoshida et al. 2003; Tsujioka et al. 2006; Blair and Miller 2012). Vitamin K has
also been used to enhance the apoptotic and inhibitory effects of pre-existing anticancer drugs, like Sorafenib, in pancreatic and liver cancers (Wei et al. 2010; Wei et
al. 2010; Carr et al. 2011). The characterization and use of organic and nutritive
compounds (like vitamin K) to induce apoptosis and inhibit cancerous cell growth is
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appealing because of the resulting lack of damage to healthy cells, as well as the
benefits to the immune system and implications for prevention (Mora et al. 2008).

Vitamin K. Vitamin K represents a class of fat-soluble, structurally similar
vitamins that are known for their role as a cofactor in the post-translational
modification (carboxylation) of proteins involved in blood coagulation and bone
metabolism, which allows them to bind calcium ions, as well as in the regulation of
cellular processes (Higdon 2000; Ehrlich 2013). Structurally, this group of vitamins
is characterized by a naphthoquinone ring and a side chain consisting of 5-carbon
units that vary in length, branching, and degree of unsaturation (Fieser et al. 1941;
National Institute of Health 2015). There are two natural analogs of vitamin K –
vitamin K1 (VK1) or phylloquinone and vitamin K2 or menaquinones (Higdon
2000). Phylloquinone is a phytochemical and metabolite of photosynthesis, where it
functions as an electron carrier during photophosphorylation in chloroplasts (Marks
1975). Phylloquinone is primarily obtained through the dietary intake of higher
order plants (National Institute of Health 2015). This analog of vitamin K is more
saturated than menaquinones, containing only one double bond in its side chain,
and is composed of the characteristic naphthoquinone ring and a four-unit side
chain (Figure 1) (National Center for Biotechnology Information 2015).
Menaquinones, in contrast, are a group of compounds that are synthesized by
intestinal microbiota from animal products (i.e. meat, dairy), as well as fermented
foods (Higdon 2000). Menaquinones consist of homologs that vary in the length of
their unsaturated side chain and where each side chain unit contains a double bond,
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and range from MK-2 through MK-14 (Higdon 2000; National Center for
Biotechnology Information 2015; National Institute of Health 2015). Menaquinones
are named according to the number of 5-carbon side chain units they contain, so
that MK-4, for example, contains four side chain units (Higdon 2000). There are
several types of synthetic vitamin K, with the most recognized being vitamin K3 or
menadione (Higdon 2000; Council for Responsible Nutrition 2013). Menadione is a
derivative of vitamin K, containing only the naphthoquinone ring, and is inactive
until in vivo alkylation occurs (Higdon 2000; National Center for Biotechnology
2015). Unlike phylloquinone and menaquinones, the synthetic isomers of vitamin K,
including menadione, are associated with toxicity (e.g. allergic reactions and
hemolytic anemia) in large doses (Council for Responsible Nutrition 2013).

Figure 1: Structure of Phylloquinone. 2d chemical structure of
phylloquinone or vitamin K1, IUPAC: 2-methyl-3-[(2E)-3,7,11,15tetramethylhexadec-2-en-1-yl]napthoquinone (Source: ChemSpider).

Phylloquinone, Apoptosis, and Cancer Therapy
Both natural analogs of vitamin K, phylloquinone and menaquinones, as well
as synthetic menadione, have been shown to be involved in the induction of
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apoptosis and inhibition of cancer cell growth, both in vitro and in vivo (Yaguchi et
al. 1997; Yoshida et al. 2003; Hitomi et al. 2005; Criddle et al. 2006; Tsujioka et al.
2006; Zhang et al. 2006; Wei et al. 2010; Wei et al. 2010; Carr et al. 2011; Zhang et
al. 2012; Karasawa et al. 2013; Suresh et al. 2013; Linsalata et al. 2015; Orlando et
al. 2015). The apoptotic and anti-proliferative effects of phylloquinone have been
examined in a number of cancer types, including colon, gastric, liver, and pancreatic
(Wei et al. 2010; Wei et al. 2010; Carr et al. 2011; Linsalata et al. 2015; Orlando et al.
2015). One study examined these effects of phylloquinone in three colon cancer cell
lines and found treatment with increasing concentrations of phylloquinone (10 μM
to 200 μM) resulted in reduced cell growth and increased rates of apoptosis
(Orlando et al. 2015). In addition, this study found phylloquinone modified the
proliferative Ras/Raf/MEK/ERK pathway and significantly increased the ratio of
Bax/Bcl-2 at concentrations of 100 μM or higher (Orlando et al. 2015). Another
study looked at the effects of increasing concentrations of phylloquinone (10 μM to
200 μM) in gastric and colon cancer cell lines and found a concentration-dependent
inhibition of cell proliferation and increased rates of apoptosis, particularly in colon
cancer cells (Linsalata et al. 2015). This study also found decreased phosphorylation
to members of the Ras/Raf/MEK/ERK pathway, as well as decreased polyamine
biosynthesis, to be involved in these effects (Linsalata et al. 2015).
Two studies examined the effects of phylloquinone in combination with
sorafenib, a small molecule tyrosine kinase inhibitor, and found the combined use of
these compounds significantly elevated their apoptotic and inhibitory effects in both
human and rodent hepatocellular carcinomas, compared to the separate use of both
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compounds (Wei et al. 2010; Carr et al. 2011). These studies found the separate use
of phylloquinone and sorafenib decreased phosphorylation of the calciumdependent Ras/Raf/MEK/ERK pathway, upregulated p53, and increased the
localization of several intrinsic inducers of apoptosis, including Bak and Bax,
however, using these compounds together significantly enhanced their anti-cancer
molecular modifications (Figure 2) (McCubrey et al. 2007; Wei et al. 2010; Carr et al.
2011). In addition to synergistically increasing the anti-cancer effects of one
another, these studies found that the dosage of sorafenib (2.5 μM) and
phylloquinone (25 μM) could be reduced and still produce the same effects (Wei et
al. 2010; Carr et al. 2011). Another study examined the ability of phylloquinone and
sorafenib to induce apoptosis and inhibit cell growth, both alone and combination,
in pancreas adenocarcinoma cell lines, and found the separate use of these
compounds produced insignificant anti-cancer effects, but when used in
combination, there was a strong association with apoptosis and cell growth
inhibition (Wei et al. 2010). This study also found that the combined use of
phylloquinone and sorafenib activated effector caspase 3, initiator caspase 8, and
intrinsic inducer of apoptosis, Bid, as well as inhibited proliferative pathway,
Ras/Raf/MEK/ERK (Wei et al. 2010). Lastly, this study again found that by
combining phylloquinone and sorafenib, they could reduce the dosage of each
compound (2.5 μM and 25 μM, respectively) and still produce the same effects (Wei
et al. 2010).
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Figure 2: Members of the Intrinsic and Extrinsic Apoptotic Pathways Affected
by Phylloquinone in Liver and Pancreatic Cancers. Some members of the
intrinsic or mitochondrial and extrinsic or death receptor pathway that have been
shown to be modified following treatment with phylloquinone, alone or in
combination with Sorafenib – a small tyrosine kinase inhibitor (McCubrey et al.
2007; Wei et al. 2010; Wei et al. 2010; Carr et al. 2011; modified from Panayi et
al. 2013).

These studies document the apoptotic and inhibitory effects of
phylloquinone, whether used alone or in combination with an anti-cancer drug, and
in doing so, demonstrate its chemotherapeutic and cytotoxic potential. There are,
however, a fundamental lack of studies validating these effects, when compared to
the chemotherapeutic utilization of menaquinones and menadione, and therefore,
further characterization of phylloquinone is needed. Exploring the anti-cancer
effects of phylloquinone could provide us with a better understanding of the
mechanisms governing apoptosis and how tumor cells are able to modify these
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mechanisms to promote tumorigenesis and metastasis. In addition, further
characterization of phylloquinone would help to support its ability to enhance
apoptosis and diminish cancer cell growth, and may lead its use as an anti-cancer
drug, alone or in combination with other regulators of these processes.

Hypothesis, Rationale, and Specific Aims
This study seeks to verify the apoptotic and inhibitory effects of
phylloquinone in a non-Hodgkin lymphoma cell line, known as U937. Through the
examination of preliminary data and pertinent literature, the following hypotheses
were made: (1) Treatment with phylloquinone will increase the frequency of
apoptosis. (2) Treatment with phylloquinone will result in U937 cells with larger
areas, which is attributed to membrane blebbing or macrophage differentiation
(Blair and Miller 2012). (3) Treatment with phylloquinone will have an antiproliferative effect on U937, resulting in decreased cell density. (4) Higher
concentrations of phylloquinone and longer treatment times will enhance these
effects, resulting in greater rates of apoptosis, less remaining viable U937 cells, and
cells with even larger areas. These hypotheses are based on a preliminary study that
was conducted in 2012, in which I a concentration-dependent reduction in U937
was observed and attributed to the induction of apoptosis. An increase in cell area
was also observed and attributed to an increase in membrane blebbing and
macrophage differentiation, as a result of apoptosis (Blair and Miller 2012). These
experiments will be replicated and modified, in order to verify the occurrence of
apoptosis.

31

This study will examine the ability of phylloquinone to reduce U937 cell
growth through the induction of apoptosis in both a concentration- and timedependent manner, in order to better characterize its effects, as well as to establish
an experimental protocol. The effects of phylloquinone will be assessed through the
quantification of U937 cell density and area, as well as through the use of molecular
markers for apoptotic cell death to both verify and quantify its occurrence. The
results of this study will provide evidence of the anti-cancer potential of
phylloquinone, as well as will provide insight into its effects in a non-Hodgkin
lymphoma cell line.
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CHAPTER 2
MATERIALS AND METHODS

Experimental Design
The first aim of this study was to repeat the preliminary experiment, in order
to verify the concentration-dependent reduction in U937 cell numbers, following
treatment with several concentrations of phylloquinone (Blair and Miller 2012). In
order to accomplish this, a series of experiments using the same parameters as the
first study, such as treatment concentrations of 0, 10, 50, 100, or 500 μM
phylloquinone and a treatment time of 7 days, were conducted (Table 1). Cell
densities were determined for each control or treatment group. The second aim of
this study was to establish an experimental protocol, in regards to phylloquinone
concentration and treatment duration. This was accomplished by conducting
several time series experiments, in which U937 densities were determined every 24
hours for 4 days (Table 1). In addition, a narrower range of treatment
concentrations (0, 100, or 500 μM) was selected. These experiments led to selection
of a 48-hour treatment time, as well as the continued use of 100 or 500 μM
phylloquinone, for all future experiments (Table 1). The third aim of this research
was to show that phylloquinone does induce apoptosis, as well as to show that this
type of cell death is responsible for the resulting effects on cell density and area. To
complete this, immunofluorescence assays were utilized to label cell surface and
nuclear markers for apoptosis, which allowed the classification of individual cells as
'apoptotic' or 'non-apoptotic' (Table 1). Overall cell densities were determined at
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the conclusion of each experiment. Afterwards, cells were incubated with
fluorescently conjugated antibodies, wet mounted onto slides, and photographed.
U937 cell areas were determined from these photographs. The fourth aim of this
research was to demonstrate that higher concentrations of phylloquinone increase
the frequency of apoptosis. This was completed by examining the proportion of cells
labeled apoptotic from random field view photographs taken during
immunofluorescence. Further details on experimental methodology and analysis are
provided below.

No.

Date

Duration
(days)

No. of
Samples

No. of
Concentrations

Description

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

5-23-14
6-9-14
7-11-14
8-1-14
8-1-14
9-10-14
10-1-14
11-3-14
2-7-15
2-9-15
3-10-15
5-18-15
8-5-15
8-13-15
8-24-15
8-28-15
9-24-15
9-24-15

7
7
4
4
7
4
2
2
2
2
2
2
2
2
2
2
2
2

10
10
3
3
12
3
6
6
12
12
6
6
6
6
6
6
6
6

4
4
2
2
4
2
2
2
2
2
2
2
2
2
2
2
2
2

Cell Density
Cell Density
Cell Density, Time Series
Cell Density, Time Series
Cell Density
Cell Density, Time Series
Cell Density, Cell Area
Cell Density, Cell Area
Cell Density
Cell Density
Cell Density, Cell Area, Annexin V
Cell Density, Cell Area, Annexin V
Cell Density, Cell Area, APO-BrdU
Cell Density
Cell Density
Cell Density, Cell Area, APO-BrdU
Cell Density, Cell Area, APO-BrdU
Cell Density, Cell Area, Annexin V

Table 1: Experiment List. List of experiments (N = 18) containing the date,
duration, number of samples, number of phylloquinone concentrations, and a
description of the type of data collection – cell density, area, and/or the occurrence
of apoptosis (i.e. annexin V or APO-BrdU).
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U937 Cell Line and Cell Culture
U937 cells were provided by the American Type Culture Collection (ATCC,
Manassas, VA, United States). U937 were isolated from a histiocytic pulmonary or
non-Hodgkin lymphoma of a 37-year-old Caucasian male (Sundström and Nilsson
1976; Sigma-Aldrich 2015). This non-adherent cell line exhibits the morphology of
monocytes, but is capable of adopting the morphology of macrophages (Figure 3)
(Passmore et al. 2001; Sigma-Aldrich 2015). U937 cells were maintained and
cultured in RPMI-1640 with L-glutamine and sodium bicarbonate (Fisher Scientific,
United States). Cell media was supplemented with 20% fetal bovine serum (FBS)
(Sigma-Aldrich, United States). U937 cells were subcultured on a weekly basis at a
1:5 ratio of cells to media for a total volume of 30 ml per culture flask. All cell
cultures were incubated and maintained at 37°C and 5% CO2.

Experimental Culture Conditions
Cell culture experiments were set-up with an initial cell density of 1 x 105 or
2 x 105 cells/ml, depending on the particular experiment (Table 1). Cell stock
densities were obtained via hemocytometer counts and adjusted to the specified
concentration by diluting with supplemented media containing the appropriate
concentration of phylloquinone (0, 10, 50, 100, or 500 μM). Cell media containing
phylloquinone was diluted from a stock solution of 500 μM phylloquinone in 0.5%
ethanol and supplemented cell media (RPMI-160 with 20% FBS) (see
"Phylloquinone Solution", below). Cells were cultured in 12-well culture plates, with
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a total volume of 3 ml of solution per well and incubated at 37°C and 5% CO2 for 24
hours to 7 days, depending upon the experiment (Table 1).

Figure 3: U937 cells at 20x magnification. Image of wet mount of untreated
U937 cells at 20x magnification. The majority of the cells in this image exhibit the
morphology of monocytes, while several exhibit the morphology of macrophages.

Phylloquinone Solution
A 500 μM phylloquinone stock solution was prepared by dispensing 4.6 μl
phylloquinone (Sigma-Aldrich, United States) into 100 μl of ethanol and 2 ml of prewarmed media (37°C) supplemented with FBS. This solution was briefly vortexed
and diluted to 20 ml with additional warmed media. A 7 ml aliquot of 500 μM
phylloquinone stock was transferred to a 15 ml conical tube and stored in a water
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bath at 37°C until plating. Other concentrations of phylloquinone were made by
diluting aliquots of the 500 μM stock solution to the appropriate concentration of
phylloquinone (10, 50, or 100 μM) with 37°C supplemented media, for a total
volume of 7 ml per each treatment concentration (Table 2). An aliquot of media
containing 0 μM phylloquinone was created by diluting 35 μl of ethanol to 7 ml with
pre-warmed RPMI-1640 supplemented with 20% FBS. Each aliquot was stored at
37°C until use.

Phylloquinone Concentration
(μM)

Volume of 500
μM Stock (ml)

Volume of Supplemented
Media (ml)

0
10
50
100
500

0.00
0.14
0.70
1.40
7.00

6.97*
6.86
6.30
5.60
0.00

Table 2: Phylloquinone Treatment Solution. Composition of
phylloquinone solution by volume of 500 μM stock and
supplemented media for each treatment concentration, for a total of
7 ml per concentration. * The difference in volume in the control (0
μM) is due to the presence of ethanol (35 μl).

Cell Culture Preparation
After establishing U937 cell stock density with hemocytometer counts, the
appropriate volume of cell stock needed for 7 ml of solution with 1 x 105 or 2 x 105
cells/ml was calculated. This volume was pipetted first from the 7 ml aliquot of
supplemented media intended for the control U937 group and replaced with the
same volume of U937 cell stock. The cell-media aliquot was homogenized by
inversion and 3 ml of this solution was dispensed into each control well. This
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procedure was repeated for each treatment group, until all culture wells contained 3
ml of U937 at the calculated density, with 0, 10, 50, 100, or 500 μM phylloquinone in
supplemented media. The U937 stock culture flask and cell-media aliquots were
gently inverted between pipetting to ensure homogenization.

Data Collection

Cell Density and Area Determination
U937 cell densities were determined at the end of each experiment using a
hemocytometer (Figure 4). Eight counts were conducted per control or treatment
group, and averaged. Care was taken to homogenize the culture plate before
sampling. U937 cell areas were determined by photographing wet mounted slides of
each group and measured using an image analysis program, called ImageJ, U.S.
National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/.
Cell areas were also determined following immunofluorescence assay (see
“Determination of Apoptosis”, below). For non-assayed cell areas, four random
bright-field images were taken at 20x magnification (Figure 4). For assayed cells,
each image was taken twice – once using fluorescence microscopy and once using
bright-field microscopy – in order to distinguish between apoptotic and nonapoptotic cells. Fluorescent photographs were taken using the green excitation
filter. The red excitation filter was also used to view the cells to ensure they were
not auto-fluorescing. As before, four random images of each slide were taken at 20x
magnification. Care was taken to minimize the amount of time each slide was
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exposed to light to avoid photobleaching. Overall, apoptotic, and non-apoptotic
U937 cells were measured and distinguished between using ImageJ. To do this,
ImageJ was calibrated to a known distance at 20x magnification. The freehand lasso
tool was then used to select the perimeter of each cell in an image. Overall cell areas
were measured and analyzed by treatment group, as well as separately on the basis
of fluorescence (where applicable), which was used as an indicator of apoptosis.

Figure 4: Cell Density, Cell Area, and Percent Apoptosis Flowchart. Flowchart
outlining U937 cell density, cell area, and percent apoptosis determination.
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Determination of Apoptosis
Apoptotic U937 cells were labeled using either the Annexin V-FITC Apoptosis
Detection Kit (Sigma-Aldrich, United States) or APO-BrdU™ TUNEL Assay Kit, with
Alexa Fluor® 488 Anti-BrdU (Sigma-Aldrich, United States) (Figure 5). Both assays
utilize fluorescently conjugated antibodies to visualize biochemical changes
characteristic of apoptosis. The annexin V protein was provided as part of the
Annexin V FITC Apoptosis Detection Kit, which labels phosphatidylserine residues
with annexin V conjugated to Alexa Fluor® 488. Phosphatidylserine is a
phospholipid that is translocated from the inner-to-outer cell membrane early on in
apoptosis. Annexin V has a high binding affinity for phosphatidylserine and binds to
it preferentially, emitting fluorescence at the cell's surface that is detectable under
UV light (van Engeland et al. 1998). The BrdUTP substrate and antibody were
supplied with the APO-BrdU™ TUNEL Assay Kit. BrdUTP is a substrate that binds to
3'-hydroxyl ends of DNA, which are exposed following fragmentation in late stage
apoptosis. The anti-BrdU anti-body included in this kit is fluorescently labeled with
Alexa Fluor® 488 and binds to BrdUTP with high affinity, emitting nuclear
fluorescence that is detectable under UV light (ThermoFisher Scientific 2015).

Annexin V Assay. The Annexin V-FITC Apoptosis Detection Kit was used to
label apoptotic cells according to the following procedure (Figure 5). Following cell
density determination, the contents of each well were collected and dispensed into
separate 15 ml conical tubes. Each well of the culture plate was rinsed with 3 ml of
cold (4°C) phosphate-buffered saline (PBS) and this was also dispensed into the

40

appropriate tube. These were centrifuged at 1000 rpm for 5 minutes. Once pelleted,
the supernatant was poured off and the cells were washed in 1 ml of cold PBS,
transferred to 1.5 ml microcentrifuge tubes, and re-pelleted by centrifugation at
1000 rpm for 5 minutes. The Annexin V Incubation Reagent was prepared by
combining 10 μl of 10X Binding Buffer, 1 μl of Annexin-V conjugate, and 79 μl of
deionized water, per cell sample. Care was taken to minimize reagent light exposure,
and all components were stored on ice. Each sample was resuspended in 90 μl of
reagent and incubated in the dark for 15 minutes at room temperature. The samples
were then centrifuged for 5 minutes at 1000 rpm, pelleted, and washed with room
temperature 0.5 ml 1X Binding Buffer, which was diluted from 10X Binding Buffer
with deionized water. Following centrifugation, cells were resuspended in 100 μl of
Binding Buffer and separately wet mounted to glass microscope slides. Glass
coverslips were applied and slides were allowed to sit for several minutes before
being transferred to the microscope. Samples were viewed and photographed
within 2 hours.

APO-BrdU Assay. The APO-BrdU™ TUNEL Assay Kit was used to label
apoptotic cells according to the following procedure (Figure 5). Following density
determination, the contents of each well were collected as described above
(“Annexin V Assay”). The samples were centrifuged at 1000 rpm for 5 minutes and
resuspended in 5 ml of 1% paraformaldehyde (PFA) in PBS. Cells were fixed on ice
for 5 minutes. The samples were then centrifuged for 5 minutes at 1000 rpm and
washed in 5 ml of cold (4°C) PBS. This wash was repeated and each sample was
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resuspended in 0.5 ml of PBS. To each test tube, 5 ml of ice-cold 70% ethanol was
added. Cells were stored overnight at -20°C. The following day, the samples were
allowed to come to room temperature and centrifuged at 1000 rpm for 5 minutes.
Each sample was resuspended in 1 ml of wash buffer, transferred to 1.5 ml
microcentrifuge tubes, and centrifuged at 1000 rpm for 5 minutes. This wash was
repeated. The DNA-labeling solution was prepared by combining 10 μl of reaction
buffer, 0.75 μl of TdT enzyme, 8.0 μl of BrdUTP, and 31.25 μl of deionized water, per
cell sample. Each sample was resuspended in 50 μl of this solution and incubated
for 60 minutes in a water bath at 37°C. Care was taken to invert the samples every
15 minutes, in order to keep the cells in suspension. Following incubation, 1 ml of
rinse buffer was added to each sample and these were centrifuged at 1000 rpm for 5
minutes. This wash was repeated. The antibody staining solution was prepared by
combining 5.0 μl Alexa Fluor® 488 dye-labeled anti-BrdU antibody with 95 μl of
rinse buffer, per cell sample. Care was taken to minimize reagent light exposure, and
all components were stored on ice. Each sample was resuspended in 100 μl of this
solution and incubated for 30 minutes in the dark at room temperature. Following
incubation, the contents of each tube were wet mounted to glass microscope slides.
Glass coverslips were applied and slides were allowed to sit for several minutes
before being transferred to the microscope. Samples were viewed and
photographed within 2 hours.
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Annexin
V Assay

APO-BrdU
Assay

Figure 5: Annexin V and APO-BrdU Assay Flowchart. Flowchart outlining the
annexin V and APO-BrdU assay binding protocols used for these experiments.
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Analysis

Occurrence of Apoptosis Analysis
The occurrence of apoptosis was determined as a percent (Table 3). Percent
apoptosis was calculated as the number of cells labeled with annexin V or APOBrdU, relative to the total number of assayed cells, by treatment group.

Cell Area Analysis
GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla,
California, USA, www.graphpad.com and IBM SPSS software were used to analyze
cell area data and create cell area figures (Figures 9 - 19). Cell areas were analyzed
by treatment concentration, as well as between apoptotic or non-apoptotic groups,
using a one-way analysis of variance (ANOVA). A one-way ANOVA was selected to
test whether there is a significant difference between the variances of cell area
(dependent variable) by treatment concentration (independent variable).

Cell Density Analysis
GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla,
California, USA, www.graphpad.com, Minitab, and IBM SPSS software were used to
obtain statistics and create cell density figures (Figures 20 – 26). Cell densities were
analyzed by treatment concentration and/or time, using a one- or two-way analysis
of variance (ANOVA). A one-way ANOVA was selected to test whether there is a
significant difference between the variances of cell density (dependent variable) by
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treatment group (independent variable). A two-way ANOVA was selected to test
whether there is a significant difference between the variances of cell density
(dependent variable) by treatment concentration and time (independent variables).
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CHAPTER 3
RESULTS

Occurrence of Apoptosis
The occurrence of apoptosis was determined for all assayed cells, following
treatment with 0, 100, or 500 μM phylloquinone for 48 hours (Table 3). Apoptosis
was examined as a percent. Percent apoptosis was calculated from the number of
cells binding annexin V or APO-BrdU relative to the total number of assayed cells for
that treatment group. The percent apoptosis for cells treated with 100 or 500 μM
phylloquinone is 49.7% and 60.6%, respectively, while 8.5% of cells treated with no
phylloquinone underwent apoptosis. This analysis also shows a concentrationdependent increase in the induction of apoptosis with increasing concentrations of
phylloquinone, however, the rates of apoptosis increased by only about 10% with a
fivefold increase in the concentration of phylloquinone. These results are based
upon six experimental replicates, with three of each assay type (Annexin V or APOBrdU) (Table 1).
Images of U937 cells treated with 0, 100, and 500 μM phylloquinone labeled
with annexin V are shown below (Figure 6). Cells that are fluorescent, or positive for
the binding of annexin V, are considered to be in the early stages of apoptosis. These
images show treatment with 100 μM phylloquinone increases the frequency and
intensity of the binding of annexin V, as well as reduces cell density and increases
cell area. These images also show treatment with 500 μM phylloquinone enhances
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these effects, resulting in higher and more intense binding of annexin V and even
less remaining U937 cells with larger areas.

Phylloquinone
Concentration
(μM)
0

No. of annexin
V binding cells

Total number of
apoptotic cells

17

No. of APOBrdU binding
cells
57

Percent
apoptosis

74

Total
number of
cells
867

100

297

129

426

858

49.7%

500

309

219

528

871

60.6%

8.5%

Table 3: Occurrence of Apoptosis Following Treatment with 0, 100, or 500 μM
Phylloquinone for 48 Hours. Percent apoptosis determined from the number of
U937 cells binding annexin V or APO-BrdU relative to the total number of U937 by
treatment concentration. Table contains number of annexin V or APO-BrdU binding
U937 cells, as well as the total number of apoptotic cells, total number of measured
cells, and percent apoptosis, following treatment with phylloquinone (0, 100, or 500
μM) at 48 hrs. Table represents the results of six different experiments (N=6).

0 μM phylloquinone

100 μM phylloquinone

500 μM phylloquinone

Figure 6: U937 Cells Binding Annexin V Following Treatment with 0, 100, or
500 μM Phylloquinone for 48 Hours. Images of U937 cells at 20x magnification
following treatment with increasing concentrations of phylloquinone (0, 100 or
500 μM) at 48 hrs. Apoptotic cells are labeled with annexin V conjugated to Alexa
Fluor 488.
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Cell Area
U937 cell areas were determined following treatment with 0, 100, or 500 μM
phylloquinone for 48 hours (Figure 7, Table 1). Cell areas were analyzed on the
basis of phylloquinone concentration, by apoptotic and non-apoptotic groups, and
by assay type (i.e. Annexin V or APO-BrdU). Overall cell areas were determined from
all experiments where cell areas were collected, without regard to apoptotic or nonapoptotic groups, and show a concentration-dependent increase in mean cell area
following treatment with increasing concentrations of phylloquinone (Figure 7). The
mean cell area of cells treated with no phylloquinone is 0.162 μm2, while the mean
cell areas of cells treated with 100 or 500 μM phylloquinone are 0.173 μm2 and
0.199 μm2, respectively. This data represents the results of eight experimental
replicates. This data were analyzed using a one-way ANOVA. The results of this
analysis indicate overall U937 area varies significantly between control and
treatment groups, and increases with increasing phylloquinone concentrations (F
(2, 3020) = 12.994, p < 0.001).
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Figure 7: Mean Cell Area Following Treatment with 0, 100, or 500 μM
Phylloquinone for 48 Hours. Mean U937 cell area following treatment with
increasing concentrations of phylloquinone (0, 100 or 500 μM) at 48 hrs. Data
represents the results of eight different experiments (N = 8) (mean ± SEM). Data
were analyzed by a one-way ANOVA (F (2, 3020) = 12.994, p < 0.001).

The distribution of all U937 cell areas is unimodal and positively skewed,
with areas ranging from 0.0 to 2.0 μm2 (Figure 8). This distribution shows the
majority of cells have areas that are concentrated to the left, with several outliers at
2.0 μm2. The distribution of cell areas are shown for each concentration of
phylloquinone (0, 100, or 500 μM) and these follow the same trend as mean cell
area, in that, cells treated with phylloquinone are larger and occupy an area nearer
to the right of the distribution, while untreated or control cells are smaller and
occupy an area to the left of the distribution. In addition, cells treated with a higher
concentration of phylloquinone (500 μM) have areas that are larger than cells
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treated with a lower concentration of phylloquinone (100 μM). The range of cell
area also varies between each group, with untreated cells exhibiting the most
narrow spread (0.02 to 0.45 μm2), and cells treated with the higher phylloquinone
concentrations exhibiting progressively wider ones - 0.03 to 0.61 μm2 for 100 μM
phylloquinone and 0.04 to 2.0 μm2 for 500 μM phylloquinone. This data represents
the results of eight experimental replicates and indicates increasing concentrations
of phylloquinone result in cells with larger areas.
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Figure 8: Distribution of Cell Area Following Treatment with 0, 100, or 500
μM Phylloquinone for 48 Hours. Distribution of U937 cell area following
treatment with increasing concentrations of phylloquinone (0, 100, or 500 μM) at
48 hrs. Data represents the results of eight different experiments (N = 8).
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U937 cell areas were also determined for both apoptotic and non-apoptotic
cells following treatment with 0, 100, or 500 μM phylloquinone at 48 hours (Figures
9 - 19). Cells that were identified as apoptotic due to their binding of annexin V
exhibit a concentration-dependent increase in cell area with increasing
concentrations of phylloquinone, so that untreated apoptotic cells have the smallest
mean area (0.091 μm2), cells treated with a lower concentration of phylloquinone
(100 μM) have the second largest mean area (0.098 μm2), and cells treated with a
higher concentration of phylloquinone (500 μM) have the largest mean area (0.108
μm2) (Figure 9). This data represents the results of three experimental replicates. A
one-way ANOVA was used to analyze mean areas of annexin V binding cells by
treatment group. The results of this analysis indicate there is a significant difference
between the mean areas of untreated and treated groups of early apoptotic U937
cells, as well as shows that the mean area of apoptotic U937 cells increases with
increasing concentrations of phylloquinone (F (2, 620) = 4.069, p < 0.05).
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Figure 9: Mean Area of Annexin V Binding Cells Following Treatment with 0,
100, or 500 μM Phylloquinone for 48 Hours. Mean area of annexin V binding
U937 cells following treatment with increasing concentrations of phylloquinone (0,
100 or 500 μM) at 48 hrs. Data represents the results of three different experiments
(N = 3) (mean ± SEM). Data were analyzed by a one-way ANOVA (F (2, 620) =
4.069, p < 0.05).

The distribution of cells binding annexin V is unimodal and skewed to the
right, with the majority of cell areas occupying the left of the distribution and areas
that range from 0.04 to 0.40 μm2 (Figure 10). Cells area distributions are shown
relative to each concentration of phylloquinone (0, 100, or 500 μM) and follow the
same pattern as overall cell areas, in that, with increasing concentrations of
phylloquinone, the areas of early-stage apoptotic cells increase. The distribution of
annexin V binding cells shows that untreated cells are the least frequent and have
the smallest areas, while annexin V binding cells treated with 100 μM phylloquinone
are more frequent and have larger areas, and cells treated with 500 μM
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phylloquinone are the most frequent and have the largest areas. The range of
annexin V binding cell areas also varies between treatment group, so that cells
treated with 0 μM phylloquinone have the most narrow spread (0.05 to 0.12 μm2),
while cells treated with 100 μM have a wider range (0.04 to 0.22 μm2) and cells
treated with 500 μM have the widest range (0.05 to 0.40 μm2). This data represents
the results of three experimental replicates and indicates early-stage apoptotic cells
have larger areas with increasing concentrations of phylloquinone.
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Figure 10: Distribution of Annexin V Binding Cell Area Following Treatment
with 0, 100, or 500 μM Phylloquinone for 48 Hours. Distribution of annexin V
binding U937 cell area following treatment with increasing concentrations of
phylloquinone (0, 100, or 500 μM) at 48 hrs. Data represents the results of three
different experiments (N = 3).
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U937 cells that did not bind annexin V, and were thus identified as nonapoptotic, also increase in response to treatment with phylloquinone, as well as
exhibit a concentration-dependent increase in cell area following treatment with
higher phylloquinone concentrations (Figure 11). Mean cell areas reveal that nonapoptotic U937 cells treated with 0 μM phylloquinone have the smallest mean area
(0.116 μm2), while cells treated with 100 and 500 μM have larger areas (0.145 and
0.151 μm2, respectively). This data was collected from three experimental
replicates. A one-way ANOVA was used to analyze mean area of non-apoptotic U937
following treatment with phylloquinone. The results of this analysis suggest there is
a significant difference between the mean area of non-apoptotic U937 cells treated
with different concentrations of phylloquinone (F (2, 1004) = 18.124, p < 0.001).
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Figure 11: Mean Area of Annexin V Non-Binding Cells Following Treatment
with 0, 100, or 500 μM Phylloquinone for 48 Hours. Mean area of annexin V
non-binding U937 cells following treatment with increasing concentrations of
phylloquinone (0, 100 or 500 μM) at 48 hrs. Data represents the results of three
different experiments (N = 3) (mean ± SEM). Data were analyzed by a one-way
ANOVA (F (2, 1004) = 18.124, p < 0.001).

The distribution of areas of U937 cells which did not bind annexin V, and
were thus considered non-apoptotic, is unimodal and right-skewed, with areas
ranging from 0.02 to 1.0 μm2 (Figure 12). Again, the majority of areas are
concentrated to the left of the distribution, with the areas of untreated cells confined
to this region and the areas of cells treated with higher concentrations of
phylloquinone progressing toward the right side of the distribution. In other words,
this data follows the same trend established by preceding data, which is: the area of
non-apoptotic U937 cells increases in the presence of phylloquinone, and is
dependent upon concentration, so that higher concentrations of phylloquinone
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further increase cell area. The distribution of non-annexin V binding cell areas also
shows that while cells treated with the lower concentration of phylloquinone (100
μM) occupy a region that is further left in the distribution than cells treated with the
higher concentration of phylloquinone (500 μM), however, the spread of cell area
for the lower concentration is more variable. Cell areas of non-apoptotic U937
treated with no phylloquinone range from 0.02 to 0.60 μm2, while those treated
with 100 μM phylloquinone range from 0.03 to 1.0 μm2 and 0.04 to 0.51 μm2 for 500
μM. This data represents the represents the results of three experimental replicates,
and shows that non-apoptotic cell area increases with exposure to phylloquinone, as
well as increases in response to higher phylloquinone concentrations.
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Figure 12: Distribution of Annexin V Non-Binding Cell Area Following
Treatment with 0, 100, or 500 μM Phylloquinone for 48 Hours. Distribution of
annexin V non-binding U937 cell area following treatment with increasing
concentrations of phylloquinone (0, 100, or 500 μM) at 48 hrs. Data represents the
results of three different experiments (N = 3).
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U937 cell areas of cells that were identified as apoptotic based upon their
binding of APO-BrdU demonstrate the same trend in the relationship between cell
area and phylloquinone concentration, in that, the mean area of late-stage apoptotic
cells increase in following treatment with phylloquinone, as well as further increase
with increasing phylloquinone concentrations (Figure 13). The mean area of
apoptotic control cells (0 μM) is the smallest (0.258 μm2), while apoptotic cells
treated with 100 μM have a larger mean area (0.270 μm2), and cells treated with
500 μM phylloquinone have the largest mean area (0.414 μm2). This data represents
the results of three experimental replicates. A one-way ANOVA was used to analyze
mean areas of APO-BrdU binding cells by phylloquinone concentration (0, 100, or
500 μM). The results of this analysis indicate treatment of U937 cells with
phylloquinone increases apoptotic cell area, as well as that apoptotic cell area is
dependent on the concentration of phylloquinone, so that increasing the treatment
concentration results in increasing cell areas (F (2, 402) = 14.390, p < 0.001).
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Figure 13: Mean Area of APO-BrdU Binding Cells Following Treatment with 0,
100, or 500 μM Phylloquinone for 48 Hours. Mean area of APO-BrdU binding
U937 cells following treatment with increasing concentrations of phylloquinone (0,
100 or 500 μM) at 48 hrs. Data represents the results of three different experiments
(N = 3) (mean ± SEM). Data were analyzed by a one-way ANOVA (F (2, 402) =
14.390, p < 0.001).

The distribution of U937 binding APO-BrdU cell area is unimodal and
positively skewed, with the majority of cell areas occupying the left side of the
distribution, while several outliers are represented to the right (Figure 14). The
distribution of APO-BrdU binding cell areas range from 0.10 to 1.90 μm2, and are
shown for each phylloquinone concentration (0, 100, or 500 μM). Again, the
distribution of APO-BrdU binding cells follows the same pattern as other datasets, in
that untreated (0 μM) U937 cells are less frequent and have smaller areas (0.13 to
0.39 μm2), while cells treated with the lower concentration of phylloquinone (100
μM) are more frequent and have larger areas (0.10 to 1.90 μm2), and cells treated
with the highest concentration of phylloquinone (500 μM) are the most frequent
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and have the largest cell areas (0.10 to 1.90 μm2). It is important to note that the
range of apoptotic cell areas for U937 treated with the lower concentration of
phylloquinone contains both the smallest and largest areas, meaning that, although
the majority of apoptotic cells in this treatment group exhibit areas that are larger
than the control and smaller than the highest treatment concentration, this group
does contain a fair amount of variability. This data represents the results of three
experimental replicates and indicates late-stage apoptotic cells are larger when
treated with phylloquinone, as well as that their areas increase with increasing
concentrations of phylloquinone.
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Figure 14: Distribution of APO-BrdU Binding Cell Area Following Treatment
with 0, 100, or 500 μM Phylloquinone for 48 Hours. Distribution of APO-BrdU
binding U937 cell area following treatment with increasing concentrations of
phylloquinone (0, 100, or 500 μM) at 48 hrs. Data represents the results of three
different experiments (N = 3).

59

U937 cells that did not bind to APO-BrdU, and were thus considered to be
non-apoptotic, once again demonstrate the same increase in area, following
treatment with increasing concentrations of phylloquinone (Figure 15). The mean
cell area of non-apoptotic U937 treated with no phylloquinone is the smallest (0.237
μm2), while the mean area of cells treated with 100 μM phylloquinone is the second
largest (0.250 μm2), and lastly, the mean area of cells treated with 500 μM
phylloquinone is the largest (0.355 μm2). This was collected from three
experimental replicates. A one-way ANOVA was used to analyze the mean areas of
APO-BrdU non-binding cells. The results of this analysis indicate there is a
significant difference between the mean cell areas of each treatment group (F (2,
558) = 31.082, p < 0.001).
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Figure 15: Mean Area of APO-BrdU Non-Binding Cells Following Treatment
with 0, 100, or 500 μM Phylloquinone for 48 Hours. Mean area of APO-BrdU
non-binding U937 cells following treatment with increasing concentrations of
phylloquinone (0, 100 or 500 μM) at 48 hrs. Data represents the results of three
different experiments (N = 3) (mean ± SEM). Data were analyzed by a one-way
ANOVA (F (2, 558) = 31.082, p < 0.001).

The distribution of APO-BrdU non-binding U937 cell area is unimodal and
skewed to the right, with the mass of cell areas occupying the left side of the
distribution (Figure 16). The distribution of cell areas of APO-BrdU non-binding
cells range from 0.01 to 0.89 μm2, and are shown for each concentration of
phylloquinone (0, 100, or 500 μM). This distribution conforms to other area
distributions, in that the presence of phylloquinone produces non-apoptotic cells
with larger areas, as well as that increasing concentrations of phylloquinone result
in cells with increasingly larger areas. As before, untreated cells are the most
frequent and occupy the left-most area of the distribution (0.01 to 0.47 μm2), while
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cells treated with 100 μM phylloquinone are less frequent and occupy an area of the
distribution that is more toward the right (0.01 to 0.51 μm2) and cells treated with
500 μM phylloquinone are the least frequent and occupy an area of the distribution
that is furthest right (0.03 to 0.89 μm2). Like most other area distributions,
treatment with the highest concentration of phylloquinone result in cell areas with
the greatest spread, while untreated cells exhibit the least amount of variation in
cell area. This data represents the results of three experimental replicates and again
demonstrates that treatment with phylloquinone increases cell area, regardless of a
cell’s apoptotic state. In addition, this data also shows that increasing the
concentration of phylloquinone results in U937 cells with increasing area.
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Figure 16: Distribution of APO-BrdU Non-Binding Cell Area Following
Treatment with 0, 100, or 500 μM Phylloquinone for 48 Hours. Distribution of
APO-BrdU non-binding U937 cell area following treatment with increasing
concentrations of phylloquinone (0, 100, or 500 μM) at 48 hrs. Data represents the
results of three different experiments (N = 3).

The distribution of both annexin V and APO-BrdU binding cell area, which
were identified as apoptotic, is unimodal and positively skewed, with the majority of
cell areas binding annexin V occupying the left side of the distribution and the
majority of cell areas binding APO-BrdU occupying the right side of the distribution
(Figure 17). This distribution suggests early-stage apoptotic cells, bound to annexin
V, have smaller cell areas than late-stage apoptotic cells, bound to APO-BrdU. In
addition, the spread of annexin V binding cell areas is narrower than the spread of
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APO-BrdU binding cells, which indicates cells experiencing apoptosis vary less in
size in during early apoptosis and more during late-stage.
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Figure 17: Distribution of Annexin V and APO-BrdU Binding Cell Area
Following Treatment with 0, 100, or 500 μM Phylloquinone for 48 Hours.
Distribution of annexin V and APO-BrdU binding U937 cell area following
treatment with increasing concentrations of phylloquinone (0, 100, or 500 μM) at
48 hrs. Data represents the results of six different experiments (N = 6).

The distribution of both annexin V and APO-BrdU non-binding cell area is
also unimodal and skewed to the right, with the majority of non-apoptotic cells
occupying the left region of the distribution (Figure 18). This distribution indicates a
difference between non-apoptotic U937 in the presence of annexin V or APO-BrdU,
with those not bound to annexin V generally exhibiting smaller cell areas and those
not bound to APO-BrdU exhibiting larger ones. The spread of cell area by assay type,
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however, is more consistent, with both annexin V and APO-BrdU cells exhibiting
similar ranges in cell area. This data suggests that although there is some difference
between cell areas of non-apoptotic U937 in the presence of either annexin V or
APO-BrdU, non-apoptotic cell area is less variable than apoptotic area.

300
An n exin V Non -Bin d in g
AP O -Brd U Non -Bin d in g

250

Frequenc y

200

150

100

50

0
0.0

0.5

1.0

1.5

2.0

Cell Area (µm²)
Figure 18: Distribution of Annexin V and APO-BrdU Non-Binding Cell Area
Following Treatment with 0, 100, or 500 μM Phylloquinone for 48 Hours.
Distribution of annexin V and APO-BrdU non-binding U937 cell area following
treatment with increasing concentrations of phylloquinone (0, 100, or 500 μM) at
48 hrs. Data represents the results of six different experiments (N = 6).

The distribution of all assayed cells is also unimodal and skewed to the right,
with the majority of all apoptotic and non-apoptotic U937 cell areas occupying the
left side of the distribution (Figure 19). Apoptotic and non-apoptotic cells are
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represented by their binding or non-binding of annexin V or APO-BrdU. The
distribution of all assayed cells is consistent with the distribution of overall cell area
and is comprised of areas ranging from 0.02 to 1.90 μm2. The areas of cells binding
annexin V appear to be generally smaller than cells not binding annexin V, while
areas of cells binding APO-BrdU appear to be generally larger than cells not binding
APO-BrdU. In other words, early-stage apoptotic U937 cells exhibit smaller areas
than non-apoptotic ones, while late-stage apoptotic U937 cells have larger areas
than non-apoptotic ones. In addition, cells binding APO-BrdU appear to have the
greatest spread, indicating the areas of late-stage apoptotic U937 are the most
variable.
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Figure 19: Distribution of Annexin V and APO-BrdU Binding and Non-Binding
Cell Area Following Treatment with 0, 100, or 500 μM Phylloquinone for 48
Hours. Distribution of annexin V and APO-BrdU binding and non-binding U937 cell
area following treatment with increasing concentrations of phylloquinone (0, 100,
or 500 μM) at 48 hrs. Data represents the results of six different experiments (N =
6).

Cell Density
U937 cell densities were determined following various concentrations and
experimental durations, consisting of 0, 10, 50, 100, and 500 μM phylloquinone and
24 hours to 7 days, depending on the particular experiment (Table 1). Cell densities
analyzed by phylloquinone concentration were divided into groups based on
experimental duration, which consist of 48 hours (Figure 20) or 7 days (Figures 21
and 22), in addition to 96 hour time course experiments (Figures 23-26). Initial cell
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densities were also measured, in order to ensure plating homogeneity (Figure 27).
Mean cell density following treatment with 0, 100, or 500 μM phylloquinone for 48
hours exhibits a concentration-dependent reduction in cell density, so that cells
treated with 500 μM phylloquinone contain the least amount of viable cells, while
cell treated with 0 μM phylloquinone contain the most (Figure 20). Mean cell
densities are approximately: 297,000 cells/ml for 0 μM phylloquinone, 211,000
cells/ml for 100 μM phylloquinone, and 117,000 cells/ml for 500 μM phylloquinone.
This data was collected from twelve experimental replicates, with initial cell
densities of 200,000 cells per ml of suspension. A one-way ANOVA was used to
analyze mean cell density following treatment with 100 or 500 μM phylloquinone at
48 hours. The results of this analysis indicate there are significantly different
densities between control and treatment groups at 48 hours of treatment, as well as
that increasing concentrations of phylloquinone further inhibit U937 cell growth (F
(2, 141) = 48.086, p < 0.001).
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Figure 20: Mean Cell Density Following Treatment with 0, 100, or 500 μM
Phylloquinone for 48 Hours. Mean density of U937 cells following treatment with
increasing concentrations of phylloquinone (0, 100 or 500 μM) at 48 hrs. Data
represents the results of twelve different experiments (N = 12) (mean ± SEM). Data
were analyzed by a one-way ANOVA (F (2, 141) = 48.086, p < 0.001).

Mean cell density following treatment with 0, 10, 50, 100, or 500 μM
phylloquinone at 7 days also exhibits a concentration-dependent reduction in U937
cell numbers, with the highest amount of remaining viable cells in the control group
and the least amount remaining in the higher treatment concentration groups (100
or 500 μM phylloquinone) (Figure 21). Mean cell densities for each treatment group
are approximately: 305,000 cells/ml for 0 μM phylloquinone, 196,000 cells/ml for
10 μM phylloquinone, 140,000 cells/ml for 50 μM phylloquinone, 94,000 cells/ml
for 100 μM phylloquinone, and 95,000 cells/ml for 500 μM phylloquinone. These
results vary from the 48 hour density analysis, in that the highest treatment
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concentrations yielded cell densities that were close to one another, with a slightly
higher reduction of U937 cells treated with 100 μM phylloquinone. This data
represents the results of three experimental replicates with initial cell densities of
200,000 cells/ml. A one-way ANOVA was used to analyze mean cell density
following treatment with 100 or 500 μM phylloquinone at 7 days. The results of this
analysis suggest mean cell densities vary significantly between treatment groups at
7 days of treatment through a concentration-dependent inhibition of cell growth (F
(4, 57) = 4.417, p < 0.005).

Figure 21: Mean Cell Density Following Treatment with 0, 10, 50, 100, or 500
μM Phylloquinone for 7 days. Mean density of U937 cells following treatment
with increasing concentrations of phylloquinone (0, 10, 50, 100 or 500 μM) at 7
days. Data represents the results of three different experiments (N = 3) (mean ±
SEM). Data were analyzed by a one-way ANOVA (F (4, 57) = 4.417, p < 0.005).
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One replicate of this 7 day study was presented as a separate figure due to its
variability from other experimental results (Figure 22). A one-way ANOVA was used
to analyze this experiment. The results of this analysis indicate cell densities are
significantly different between treatment groups, although the relationship between
phylloquinone concentration and cell density varies considerably from other
experimental replicates (F (4, 17) = 4.218, p < 0.005).

Figure 22: Abnormal Mean Cell Density Following Treatment with 0, 10, 50,
100, or 500 μM Phylloquinone for 7 days. Mean density of U937 cells following
treatment with increasing concentrations of phylloquinone (0, 10, 50, 100 or 500
μM) at 7 days. Data represents the results of one experiment (N = 1) (mean ± SEM).
Data was analyzed by a one-way ANOVA (F (4, 17) = 4.218, p < 0.005).

Time course experiments consisted of treatment with 0, 100, or 500 μM
phylloquinone for 96 hours, with cell counts conducted every 24 hours. These
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experiments exhibited both a concentration- and time-dependent reduction in
viable U937 cells treated with 100 or 500 μM phylloquinone, while untreated U937
cells density increased over time (Figure 23). Following 24 hours of treatment, cells
cultured in 0 μM phylloquinone have the highest mean density, while cells treated
with 500 μM have the lowest. This relationship is maintained and enhanced over
time, so that at 96 hours of treatment, U937 cells treated with no phylloquinone
have densities that are higher than both other treatment concentrations (100 μM or
500 μM), as well as higher for the same group on previous days (24, 48, and 72
hours). The treated groups exhibit the inverse of this trend, with the largest
reduction of U937 cell densities in groups treated with 500 μM phylloquinone for 96
hours, when compared to other concentrations of phylloquinone (0 or 100 μM) and
other days (24, 48, and 72 hours). This data represents the results of three
experimental replicates with initial densities of 100,000 cells/ml. A two-way ANOVA
was conducted on cell densities following treatment with 100 or 500 μM at 24, 48,
72, and 96 hours. The results of this analysis suggest mean cell area is significantly
different between treatment concentrations and over time, and that phylloquinone
is able to exert both a concentration- and time-dependent inhibition of U937 cell
growth (F (6, 141) = 6.759, p < 0.001). The two-way ANOVA was also used to
generate two line graphs depicting estimated marginal means of cell density over
time or by phylloquinone concentration, which again depict its concentration and
time-dependent effects (Figures 24 and 25).
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Figure 23: Mean Cell Density Following Treatment with 0, 100, or 500 μM
Phylloquinone for 24, 48, 72, or 96 Hours. Mean density of U937 cells following
treatment with increasing concentrations of phylloquinone (0, 100 or 500 μM) at
24, 48, 72, or 96 hrs. Data represents the results of three different experiments (N =
3) (mean ± SEM). Data was analyzed by a two-way ANOVA (F (6, 141) = 6.759, p <
0.001).
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Figure 24: Estimated Marginal Means of Cell Density Following Treatment
with 0, 100, or 500 μM Phylloquinone Over Time (24, 48, 72, or 96 Hours).
Estimated marginal means of U937 cell density following treatment with
increasing concentrations of phylloquinone (0, 100 or 500 μM) over time (24, 48,
72, or 96 hrs). Data represents the results of three different experiments (N = 3).
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Figure 25: Estimated Marginal Means of Cell Density By Phylloquinone
Treatment Concentration (0, 100, or 500 μM) for 24, 48, 72, or 96 Hours.
Estimated marginal means of U937 cell density by phylloquinone treatment
concentration (0, 100 or 500 μM) for 24, 48, 72, or 96 hrs. Data represents the
results of three different experiments (N = 3).

U937 cell densities were also examined prior to treatment with
phylloquinone to ensure both sample and replicate homogeneity, and were analyzed
for 0, 100, or 500 μM phylloquinone (Figure 26). This data represents the results of
four experimental replicates, where initial cell densities were projected at 200,000
cells/ml. It appears that each sample had a mean initial density of slightly over this
amount (approximately 231,000 cells/ml for 0 μM phylloquinone, 234,000 cells/ml
for 100 μM phylloquinone, and 230,000 cells/ml for 500 μM phylloquinone). A oneway ANOVA was conducted on mean cell density prior to treatment with
75

phylloquinone. The results of this analysis show initial cell density does not
significantly vary between control and treatment groups, as well as shows that cells
were sufficiently homogenized before plating (F (2, 21) = 0.031, p = 0.97).

Figure 26: Mean Cell Density Prior to Treatment with 0, 100, or 500 μM
Phylloquinone for 48 Hours. Mean initial U937 cell density prior to treatment
with increasing concentrations of phylloquinone (0, 100 or 500 μM) at 48 hrs. Data
represents the results of four different experiments (N = 4) (mean ± SEM). Data
were analyzed by a one-way ANOVA (F (2, 21) = 0.031, p = 0.97).
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CHAPTER 4
DISCUSSION

The Frequency of Apoptosis is Significantly Higher in U937 Cell Populations, Following
Treatment with Phylloquinone
Percent apoptosis data indicate treatment of U937 cells with phylloquinone
results in the induction of apoptosis, as well as higher concentrations of
phylloquinone increase the frequency of apoptosis. Approximately 10% of
untreated U937 cells underwent apoptosis, while 50% of cells treated with 100 μM
phylloquinone and 60% of cells treated with 500 μM underwent apoptosis (Table
3). Although there is a concentration-dependent increase in percent apoptosis, there
is only about a 10% increase in apoptosis following a fivefold increase in the
concentration of phylloquinone. This could be caused by a number of factors
including receptor saturation, desensitization, or activation of a different apoptotic
pathway. The results of these experiments validate the role of phylloquinone in the
induction of apoptosis.

Apoptotic and Non-Apoptotic U937 Cell Areas are Larger Following Treatment with
Increasing Concentrations of Phylloquinone
Cell area data and analyses demonstrate treatment with phylloquinone
results in U937 cells with considerably larger areas, regardless if the cell is
apoptotic or not (Figures 7 – 16). In addition, this effect is concentration-dependent,
so that increasing concentrations of phylloquinone result in increasing cell areas.
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This data supports the preliminary data and is believed to be due, in part, to the
increased occurrence of apoptosis in treated cell populations (Blair and Miller
2012). The effect of increased area in non-apoptotic U937 cells treated with
phylloquinone could also be due to phylloquinone’s ability to regulate cell size
independently of cell death or because these cells were bound for death but did not
emit the signals indicative of early or late-stage apoptosis (i.e. annexin V or APOBrdU). The results of these experiments show that phylloquinone treatment
increases cell size, regardless of the status of cell death.

Early-Stage Apoptotic Cells are Smaller than Late-Stage Apoptotic Cells
Cell area data and analyses demonstrate early-stage apoptotic cells (annexin
V binding) have areas that are smaller than non-apoptotic cells (annexin V nonbinding), while late-stage apoptotic cells (APO-BrdU binding) have areas that are
larger than non-apoptotic cells (APO-BrdU non-binding) (Figures 9 – 19). This data
supports preliminary data in that it provides evidence that apoptotic cells are
ultimately larger than non-apoptotic ones (Blair and Miller 2012). This change in
cell area was originally believed to be due to membrane blebbing, however, this
event occurs earlier in apoptosis, and these changes in area do not seem to appear
until late-stage apoptosis. This increase in cell area is therefore believed to be due to
the formation of apoptotic bodies that occurs during the latter part of apoptosis,
and/or to other cellular mechanisms that could have been employed to increase the
area of apoptotic cells, such as macrophage differentiation. It is important to note
that although cells not binding annexin V or APO-BrdU have areas that increase with
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increasing concentrations of phylloquinone, there is a significant difference between
the mean area and distributions of these non-apoptotic cells. There are a number of
explanations for this difference, including changes that may have occurred to U937
cells during fixation (APO-BrdU™ TUNEL Assay), cells that were undergoing
apoptosis did not produce the signals necessary to be classified as apoptotic and
were therefore considered non-apoptotic, or again, to other cellular mechanisms
that may have been inducted following treatment with phylloquinone (Zhao et al.
2014). Regardless of the reason, the relationship between early and late-stage
apoptosis is unaffected, meaning that early-stage apoptotic cells are smaller than
late-stage ones.

Phylloquinone Inhibits U937 Cell Growth and These Effects are Enhanced Over Time
Cell density data and analyses indicate treatment with phylloquinone
reduces U937 cell growth, and that phylloquinone exerts its effects in a manner that
is both concentration- and time-dependent (Figures 20, 21, and 23 – 25). In other
words, treatment with higher concentrations of phylloquinone further reduces
U937 cell growth, while longer treatment times further enhance this effect. These
results are consistent with preliminary data and validate the inhibitory effects of
phylloquinone on U937 cell growth (Blair and Miller 2012). One replicate of these
experiments produced data that is inconsistent with reduced U937 cell viability
following treatment with phylloquinone (Figure 23). This difference in mean cell
density is believed to be due to plating heterogeneity or contamination, as data from
this replicate is considerably different from other density experiments. The results
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of these experiments confirm the inhibitory effect of phylloquinone on U937 cell
growth.
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CHAPTER 5
CONCLUSION AND FUTURE DIRECTIONS

This study was conducted in order to validate the apoptotic and inhibitory
effects of phylloquinone in the U937 cell line. These effects were assessed through
the quantification of cell density and area following treatment with phylloquinone,
as well as through assay confirmation of the occurrence of apoptosis. The results of
this study show that treatment with phylloquinone induces apoptosis, reduces cell
growth, and increases cell area, as well as higher concentrations of phylloquinone
enhance these effects. These results are significant because they document the
chemotherapeutic and cytotoxic potential of this analog of vitamin K in a carcinoma
cell line, and in doing so, support former studies involving this compound, as well as
the need for additional ones (Wei et al. 2010; Wei et al. 2010; Carr et al. 2011;
Linsalata et al. 2015; Orlando et al. 2015). The utilization of phylloquinone to induce
cell death and reduce cancer cell proliferation could lead to the development of
more effective anti-cancer drugs, as well as the discovery of other preexisting drugs
whose effects are enhanced in combination with this compound. These results are
also significant because they provide support for studies concerning the anti-cancer
effects of nutritive and organic compounds, like vitamins, which are appealing
because of their lack of damage to healthy tissues, variety of other health benefits,
like immune system enhancement, and implication for cancer prevention (Mora et
al. 2008). These results also support other findings regarding the changes in cell size
that occur during apoptosis, which consist of an initial reduction in cell area
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followed by an increase in area, which is assumed to occur as a result of membrane
blebbing or budding (Kerr et al. 1972; Majno and Joris 1995).
Future studies interested in the anti-cancer effects of this compound, alone
or in combination with other chemotherapeutic agents, can utilize this study when
selecting experimental model (i.e. cell type), phylloquinone concentration, and
treatment time. Future studies on this compound may also provide further insight
into the evasion of cell death and promotion of tumorgenesis and metastasis, and
how to intercede this behavior and dysfunction in cancer cells. These research areas
are of particular importance to our understanding of cancer development, improved
treatments, and improved prevention.
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